U.S. markets closed
  • S&P Futures

    4,530.00
    +5.75 (+0.13%)
     
  • Dow Futures

    34,951.00
    +41.00 (+0.12%)
     
  • Nasdaq Futures

    15,064.25
    +30.75 (+0.20%)
     
  • Russell 2000 Futures

    2,059.70
    +0.50 (+0.02%)
     
  • Crude Oil

    86.55
    -0.41 (-0.47%)
     
  • Gold

    1,840.60
    -2.60 (-0.14%)
     
  • Silver

    24.20
    -0.03 (-0.13%)
     
  • EUR/USD

    1.1357
    +0.0010 (+0.09%)
     
  • 10-Yr Bond

    1.8270
    -0.0380 (-2.04%)
     
  • Vix

    23.85
    +1.06 (+4.65%)
     
  • GBP/USD

    1.3624
    +0.0013 (+0.09%)
     
  • USD/JPY

    114.2750
    -0.0780 (-0.07%)
     
  • BTC-USD

    42,033.25
    -268.99 (-0.64%)
     
  • CMC Crypto 200

    997.02
    +2.27 (+0.23%)
     
  • FTSE 100

    7,589.66
    +26.11 (+0.35%)
     
  • Nikkei 225

    27,594.29
    +127.06 (+0.46%)
     

A Look At The Intrinsic Value Of Apollo Medical Holdings, Inc. (NASDAQ:AMEH)

  • Oops!
    Something went wrong.
    Please try again later.
·5 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Today we will run through one way of estimating the intrinsic value of Apollo Medical Holdings, Inc. (NASDAQ:AMEH) by projecting its future cash flows and then discounting them to today's value. Our analysis will employ the Discounted Cash Flow (DCF) model. Don't get put off by the jargon, the math behind it is actually quite straightforward.

Remember though, that there are many ways to estimate a company's value, and a DCF is just one method. If you still have some burning questions about this type of valuation, take a look at the Simply Wall St analysis model.

See our latest analysis for Apollo Medical Holdings

Crunching the numbers

We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. In the first stage we need to estimate the cash flows to the business over the next ten years. Seeing as no analyst estimates of free cash flow are available to us, we have extrapolate the previous free cash flow (FCF) from the company's last reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we discount the value of these future cash flows to their estimated value in today's dollars:

10-year free cash flow (FCF) forecast

2022

2023

2024

2025

2026

2027

2028

2029

2030

2031

Levered FCF ($, Millions)

US$73.6m

US$84.6m

US$94.0m

US$101.8m

US$108.4m

US$113.9m

US$118.6m

US$122.7m

US$126.5m

US$129.9m

Growth Rate Estimate Source

Est @ 20.54%

Est @ 14.97%

Est @ 11.07%

Est @ 8.33%

Est @ 6.42%

Est @ 5.08%

Est @ 4.15%

Est @ 3.49%

Est @ 3.03%

Est @ 2.71%

Present Value ($, Millions) Discounted @ 5.6%

US$69.7

US$75.8

US$79.7

US$81.7

US$82.3

US$81.9

US$80.7

US$79.1

US$77.1

US$75.0

("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = US$783m

The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (2.0%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 5.6%.

Terminal Value (TV)= FCF2031 × (1 + g) ÷ (r – g) = US$130m× (1 + 2.0%) ÷ (5.6%– 2.0%) = US$3.6b

Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$3.6b÷ ( 1 + 5.6%)10= US$2.1b

The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is US$2.9b. In the final step we divide the equity value by the number of shares outstanding. Relative to the current share price of US$68.6, the company appears around fair value at the time of writing. Remember though, that this is just an approximate valuation, and like any complex formula - garbage in, garbage out.

dcf
dcf

Important assumptions

The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. If you don't agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Apollo Medical Holdings as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 5.6%, which is based on a levered beta of 0.842. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Moving On:

Whilst important, the DCF calculation is only one of many factors that you need to assess for a company. It's not possible to obtain a foolproof valuation with a DCF model. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. For Apollo Medical Holdings, we've compiled three relevant factors you should assess:

  1. Risks: Case in point, we've spotted 3 warning signs for Apollo Medical Holdings you should be aware of.

  2. Future Earnings: How does AMEH's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.

  3. Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!

PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the NASDAQCM every day. If you want to find the calculation for other stocks just search here.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.